Skip to content
Home

Morgan Stanley Adjusts Price Target on Editas Medicine to $8 From $10, Maintains Underweight Rating

Posted by hostabdoIn Last Modified


MT Newswires 2022

All news about EDITAS MEDICINE, INC.

Analyst Recommendations on EDITAS MEDICINE, INC.

Sales 2022 17,1 M
–
–
Net income 2022 -222 M
–
–
Net cash 2022 361 M
–
–
P/E ratio 2022 -3,43x
Yield 2022 –
Capitalization 741 M
741 M
–
EV / Sales 2022 22,2x
EV / Sales 2023 24,5x
Nbr of Employees 264
Free-Float 99,5%

Chart EDITAS MEDICINE, INC.



Duration :


Period :




Editas Medicine, Inc. Technical Analysis Chart | MarketScreener

Technical analysis trends EDITAS MEDICINE, INC.

Short Term Mid-Term Long Term
Trends Neutral Neutral Bearish

Income Statement Evolution

Sell

Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 11,01 $
Average target price 18,47 $
Spread / Average Target 67,7%


[ad_2]